Laurien J. Zeverijn

Laurien J. Zeverijn

Auto-generated profile, based on publicly available information

Laurien J. Zeverijn

Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in The Journal of Pathology
Verified
Journal Article
Closed access
BGBirgit S Geurts
Birgit S Geurts
LZLaurien J Zeverijn
Laurien J Zeverijn
JHJade M van Berge Henegouwen
Jade M van Berge Henegouwen
HWHanneke van der Wijngaart
Hanneke van der Wijngaart
LHLouisa R Hoes
Louisa R Hoes
EVE.E. Voest
E.E. Voest

18 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
TBThomas W. Battaglia
Thomas W. Battaglia
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
GWGijs F. de Wit
Gijs F. de Wit
EVE.E. Voest
E.E. Voest
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches. Patients and Methods: Patients with dMMR/MSI tumors who exhausted standard-of-care treatment options were enrolled in the Drug Rediscovery Protocol, a pan-cancer clinical trial that treats patients with cancer based on their tumor molecular profile with off-label anticancer drugs (NCT02925234). Patients received nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks). The primary endpoint was clinical benefit (CB: objective response or stable disease ≥16 weeks). Whole-genome sequencing and RNA sequencing were performed on pretreatment tumor biopsies. Results: A total of 130 evaluable patients were enrolled with 16 different cancer types. CB was observed in 62% [95% confidence interval (CI), 53–70], with an objective response in 45% (95% CI, 36–54). After a median follow-up of 14.5 months (95% CI, 13–19), the median progression-free survival was 18 months (95% CI, 9–not reached), and the median overall survival was not reached. Whereas CB was not, or only weakly, associated with markers of adaptive immune cell infiltration, CB was strongly associated with expression of a broad set of innate immune receptors/ligands. This clearly contrasted findings in melanoma, in which markers of adaptive immunity dominated the biomarker landscape. Conclusions: Nivolumab proved highly effective in advanced dMMR/MSI tumors. Expression of key innate immune receptors/ligands was the main predictor of a good treatment outcome, contrasting findings in melanoma and strengthening the rationale for tumor type–specific biomarkers for guiding immunotherapy.

25 September 2025 in Cancer Discovery
Verified
Journal Article
Closed access
IMIris L. Mimpen
Iris L. Mimpen
TBThomas W. Battaglia
Thomas W. Battaglia
MPMiguel Parra-Martinez
Miguel Parra-Martinez
CTCatherine Toner-Bartelds
Catherine Toner-Bartelds
LZLaurien J. Zeverijn
Laurien J. Zeverijn
EVE.E. Voest
E.E. Voest
Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

1 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KVKarlijn Verkerk
Karlijn Verkerk
TWTijmen J.W.T. van der Wel
Tijmen J.W.T. van der Wel
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
ISIlse A.C. Spiekman
Ilse A.C. Spiekman
ALAdrianus de Langen
Adrianus de Langen
Purpose: To provide patients with MET-mutated advanced non–small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential biomarkers for nonresponse. Patients and Methods: In the Drug Rediscovery Protocol (NCT0295234), patients with an actionable molecular profile are treated with off-label registered drugs. Both treated and untreated patients with aNSCLC harboring MET exon 14 skipping or other MET mutations received crizotinib 250 mg BID until disease progression or intolerable toxicity. Primary endpoints were clinical benefit [CB: RECIST v1.1 confirmed partial response, complete response (CR), or stable disease ≥16 weeks] and safety. Patients were enrolled using a Simon-like two-stage design, with eight patients in stage I and if ≥1/8 patients had CB, 24 patients in stage II. Whole-genome sequencing and RNA sequencing were performed on baseline biopsies. Results: Between September 2018 and October 2022, 30 patients started treatment, and 24 were response-evaluable after completing ≥1 full treatment cycle. Two patients (8.3%) achieved CR, 13 (54.2%) partial response, and two (8.3%) stable disease. The CB rate was 70.8% [95% confidence interval (CI), 48.9–87.4], and the objective response rate was 62.5% (95% CI, 40.6–81.2). After 21.2-month median follow-up, median duration of response, progression-free survival, and overall survival were 9.3 (95% CI, 6.5–not available), 10.2 (95% CI, 6.0–20.1), and 13.0 months (95% CI, 9.0–not available), respectively. Twenty-three treatment-related grade ≥ 3 adverse events occurred in 12/30 patients (40%), causing treatment discontinuation in three (10%). One patient (achieving CR) had a tyrosine kinase domain mutation (p.H1094Y), and all other patients had MET exon 14 skipping mutations. Conclusions: Crizotinib is a valuable treatment option in METmut aNSCLC.

17 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BGBirgit S. Geurts
Birgit S. Geurts
LZLaurien J. Zeverijn
Laurien J. Zeverijn
LLLindsay V.M. Leek
Lindsay V.M. Leek
JHJade M. van Berge Henegouwen
Jade M. van Berge Henegouwen
LHLouisa R. Hoes
Louisa R. Hoes
EVE.E. Voest
E.E. Voest
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234). Patients and Methods: Patients with solid, treatment-refractory, microsatellite-stable tumors were enrolled in cohort A: breast cancer cohort harboring a TML of 140 to 290, cohort B: tumor-agnostic cohort harboring a TML of 140 to 290, and cohort C: tumor-agnostic cohort harboring a TML >290. Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint was clinical benefit [CB; objective response or stable disease (SD) ≥16 weeks]. Pretreatment tumor biopsies were obtained for whole-genome sequencing and RNA sequencing. Results: Seventy-two evaluable patients with 26 different histotypes were enrolled. The CB rate was 13% in cohort A [3/24 with partial response (PR)], 21% in cohort B (3/24 with SD; 2/24 with PR), and 42% in cohort C (4/24 with SD; 6/24 with PR). In cohort C, neoantigen burden estimates and expression of inflammation and innate immune biomarkers were significantly associated with CB. Similar associations were not identified in cohorts A and B. In cohort A, CB was significantly associated with mutations in the chromatin remodeling gene PBRM1, whereas in cohort B, CB was significantly associated with expression of MICA/MICB and butyrophilins. CB and clonal TML were not significantly associated. Conclusions: Although pembrolizumab lacked activity in cohort A, cohorts B and C met the study’s primary endpoint. Further research is warranted to refine the selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity. See related commentary by Hsu and Yen, p. 3652

1 September 2020 in Annals of Oncology
Verified
Journal Article
Closed access
LHL.R. Hoes
L.R. Hoes
HWH. van der Wijngaart
H. van der Wijngaart
JHJ.M. van Berge Henegouwen
J.M. van Berge Henegouwen
LZL.J. Zeverijn
L.J. Zeverijn
DVD.L. van der Velden
D.L. van der Velden
EVE.E. Voest
E.E. Voest